We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+19.4%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$4B
AUM Growth
+$287M
Cap. Flow
-$207M
Cap. Flow %
-5.17%
Top 10 Hldgs %
61.89%
Holding
76
New
7
Increased
10
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$48.1M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$28.8M
3
ACIU icon
AC Immune
ACIU
+$23M
4
ETNB
89bio
ETNB
+$20.2M
5
ENGN icon
enGene Therapeutics
ENGN
+$19.9M

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$106M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$75.5M
3
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$70.5M
4
GPCR icon
Structure Therapeutics
GPCR
+$53.7M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.62B
$1.31B 32.87%
21,751,284
– –
RVMD icon
2
Revolution Medicines
RVMD
$40.9B
$172M 4.29%
5,981,212
+2,000,000
+50% +$48.1M
AXSM icon
3
Axsome Therapeutics
AXSM
$12.1B
$158M 3.95%
1,981,100
-150,000
-7% -$10M
PTGX icon
4
Protagonist Therapeutics
PTGX
$8.92B
$132M 3.3%
5,744,848
– –
KYMR icon
5
Kymera Therapeutics
KYMR
$8.8B
$131M 3.29%
5,161,801
+422,797
+9% +$7.56M
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$6.87B
$129M 3.23%
4,370,024
– –
OLMA icon
7
Olema Pharmaceuticals
OLMA
$1.03B
$128M 3.21%
9,135,893
– –
IONS icon
8
Ionis Pharmaceuticals
IONS
$8.85B
$123M 3.07%
2,428,613
-1,576,000
-39% -$75.5M
KURA icon
9
Kura Oncology
KURA
$826M
$106M 2.65%
7,373,228
+642,245
+10% +$6.32M
FDMT icon
10
4D Molecular Therapeutics
FDMT
$526M
$81.2M 2.03%
4,007,413
– –
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$77.8M 1.95%
1,915,109
– –
MRUS
12
DELISTED
Merus
MRUS
$75.7M 1.89%
2,752,420
– –
RPTX
13
DELISTED
Repare Therapeutics
RPTX
$75.4M 1.89%
10,333,600
+2,041,612
+25% +$11.4M
ACIU icon
14
AC Immune
ACIU
$241M
$72.9M 1.82%
14,571,236
+7,142,857
+96% +$23M
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$69.8M 1.75%
8,774,570
-328,484
-4% -$2.2M
XOMA
16
DELISTED
Xoma
XOMA
$67.2M 1.68%
3,633,743
– –
IDYA icon
17
IDEAYA Biosciences
IDYA
$3.5B
$61.5M 1.54%
1,729,043
-3,554,446
-67% -$106M
ZYME icon
18
Zymeworks
ZYME
$1.67B
$61M 1.53%
5,870,000
– –
GHRS icon
19
GH Research
GHRS
$1.95B
$60.3M 1.51%
10,400,158
+1,125,000
+12% +$7.94M
EPIX
20
DELISTED
ESSA Pharma
EPIX
$57.7M 1.45%
8,748,629
– –
JANX icon
21
Janux Therapeutics
JANX
$950M
$49.1M 1.23%
4,579,818
– –
THRD
22
DELISTED
Third Harmonic Bio
THRD
$47.9M 1.2%
4,365,933
– –
ETNB
23
DELISTED
89bio
ETNB
$45.2M 1.13%
4,047,354
+2,201,200
+119% +$20.2M
RLAY icon
24
Relay Therapeutics
RLAY
$4.24B
$43.7M 1.09%
3,970,045
+1,604,240
+68% +$13.5M
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.2B
$41M 1.03%
890,072
-937,886
-51% -$33.1M
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2023 Portfolio in Review

As of Q4 2023, BVF Inc held 76 positions worth $4B, up 7.7% from $3.71B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc withdrew a net $207M in Q4 2023, closing 6 positions and reducing 7 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $70.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Syndax Pharmaceuticals worth $40.5M.

  • BVF Inc's largest Q4 2023 buy was Syndax Pharmaceuticals: 1,875,000 shares worth $40.5M.
  • BVF Inc added most to Revolution Medicines in Q4 2023, an estimated $48.1M increase.
  • BVF Inc's biggest Q4 2023 reduction was IDEAYA Biosciences, cutting an estimated $106M.
  • BVF Inc fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $70.5M.
  • BVF Inc's ten largest holdings make up 62% of its $4B portfolio in Q4 2023.
  • BVF Inc opened 7 new positions and closed 6 in Q4 2023.
  • BVF Inc's portfolio value rose 7.7% quarter-over-quarter to $4B.

Based on BVF Inc's 13F filing for Q4 2023, filed 14 Feb 2024.